Jarushka Naidoo: SYK signature predicts irAEs from adjuv ICI in melanoma

Jarushka Naidoo shared a post on X:

“SYK signature predicts irAEs from adjuv ICI in melanoma Clinical Cancer Research:

– In pre-Tx blood from 212pts in CM-915 (nivo or ipi/nivo) – 24-gene signature related to splenic tyrosine kinases, predicted irAEs from ipi/nivo (AUC 0.83 p<0.05)”

Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma

Authors: Kelsey R. Monson, Robert Ferguson, Joanna E. Handzlik, Jiahan Xiong, Sasha Dagayev, Leah Morales, Vylyny Chat, Anabelle Bunis, Chaitra Sreenivasaiah, Sonia Dolfi, Daniel J. Tenney, Yongzhao Shao, Iman Osman,  Jeffrey S. Weber, and  Tomas Kirchhoff.

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.